Product Information
EXFORGE HCT 10-320-25 MG TAB is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $15.4477 per EA under NDC 00078056315. Its NADAC has been published 549 times since Nov 28, 2013.
FDA first approved this application on Apr 30, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 25; 320 mg/1; mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078056315
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/7/2026
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA022314FDA Approved
4/30/2009
TE Code
AB
On Market Since
4/4/2009
Pharmacological Classes
Price Statistics
The NADAC for EXFORGE HCT 10-320-25 MG TAB has been published 549 times since Nov 28, 2013, and over the history we have for it it has risen 147.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.4477 per EA |
|---|---|
| All-time high | $15.4477 (Aug 19, 2026) |
| All-time low | $6.2477 (Nov 28, 2013) |
| 52-week high | $15.4477 |
| 52-week low | $14.9978 |
| Median price | $12.3161 |
| Average price | $11.7545 |
| Largest weekly change | +19.5% (Apr 15, 2015) |
| Weeks tracked | 549 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the amlodipine valsartan and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of EXFORGE HCT 10-320-25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EXFORGE HCT 10-320-25 MG TAB, manufactured by Novartis Pharmaceuticals Corporation, is $15.4477 per EA (NDC 00078056315), effective Aug 19, 2026.
How has the price of EXFORGE HCT 10-320-25 MG TAB changed over time?
Over the history we have for it, the NADAC for EXFORGE HCT 10-320-25 MG TAB has risen 147.3%. It has been tracked across 549 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EXFORGE HCT 10-320-25 MG TAB?
Since Nov 28, 2013, the NADAC for EXFORGE HCT 10-320-25 MG TAB has ranged from a low of $6.2477 (Nov 28, 2013) to a high of $15.4477 (Aug 19, 2026), with a median of $12.3161 per EA.
Are there cheaper alternatives to EXFORGE HCT 10-320-25 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of EXFORGE HCT 10-320-25 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EXFORGE HCT 10-320-25 MG TAB?
EXFORGE HCT 10-320-25 MG TAB (NDC 00078056315) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.